Inspire Medical Systems Stock (INSP) Dives After Reporting a Q2 Beat & Guidance Cut
Elevate Your Investing Strategy:
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Inspire Medical Systems reported revenue of $217.1 million in Q2, which surpassed analysts' estimate of $214.49 million. It was also up 11% from the $195.88 million reported in the second quarter of 2024. This was fueled by the launch of its Inspire V system in the U.S.
However, investors' hopes were hurt when Inspire Medical Systems Chairman and CEO Tim Herbert noted that 'the U.S. commercial launch is progressing slower than expected, and the timeline to complete the full transition to Inspire V has been pushed forward, which will impact financial results for the year.'
Inspire Medical Systems Guidance
Inspire Medical Systems lowered its 2025 guidance in its latest earnings report. It now expects revenue for the year to range from $900 million to $910 million, compared to its previous estimate of $940 to $955 million. This would also see it miss Wall Street's 2025 revenue estimate of $914.74 million.
Inspire Medical Systems stock was down 30.48% in pre-market trading on Tuesday, following a 3.05% rally yesterday. The shares have also decreased 29.9% year-to-date and 11.6% over the past 12 months.
The guidance cut announced by Inspire Medical Systems has already resulted in several lowered price targets, including UBS analyst Danielle Antalffy cutting her price target for INSP shares to $230 from $270.
Is Inspire Medical Systems Stock a Buy, Sell, or Hold?
Turning to Wall Street, the analysts' consensus rating for Inspire Medical Systems is Strong Buy, based on 10 Buy and three Hold ratings over the past 12 months. With that comes an average INSP stock price target of $210.09, representing a potential 61.67% upside for the shares. These ratings and price targets will likely change as analysts update their coverage after today's earnings report.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
4 hours ago
- Business Insider
QQQ ETF News, 8/7/2025
How is QQQ stock faring? The Invesco QQQ ETF has risen 1.83% over the past five days and is up 9.88% year-to-date. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. According to TipRanks' unique ETF analyst consensus, which is based on a weighted average of its holdings' analyst ratings, QQQ is a Moderate Buy. The Street's average price target of $624.63 for the QQQ ETF implies an upside of 10.1%. Currently, QQQ's five holdings with the highest upside potential are Charter Communications (CHTR), Strategy (MSTR), Atlassian Corporation (TEAM), Lululemon Athletica (LULU), and Adobe Systems (ADBE). Meanwhile, its five holdings with the greatest downside potential are Shopify (SHOP), Palantir Technologies (PLTR), Fastenal (FAST), Tesla Motors (TSLA), and Constellation Energy (CEG). Power up your ETF investing with TipRanks. Discover the ETFs with High Upside Potential, carefully curated based on TipRanks' analysis.
Yahoo
5 hours ago
- Yahoo
Robert W. Baird Remains a Buy on Inspire Medical Systems (INSP)
Inspire Medical Systems, Inc. (NYSE:INSP) is one of the top oversold NYSE stocks to buy now. Robert W. Baird analyst David Rescott maintained a Buy rating on Inspire Medical Systems, Inc. (NYSE:INSP) on August 5, setting a price target of $150.00. A medical professional performing a minimally invasive procedure while using the company's technology. The rating update came after Inspire Medical Systems, Inc.'s (NYSE:INSP) release of its fiscal Q2 2025 earnings on August 4. Inspire Medical Systems, Inc. (NYSE:INSP) generated $217.1 million in revenue in fiscal Q2 2025, reflecting an 11% rise over the same quarter last year. Gross margin for the quarter reached 84.0%, while net loss was $3.6 million. The company reported $13.3 million in adjusted net income, while adjusted diluted earnings per share were $0.45 for fiscal Q2 2025. Inspire Medical Systems, Inc. (NYSE:INSP) also announced the initiation of the full launch of the Inspire V neurostimulation system in the United States. Inspire Medical Systems, Inc. (NYSE:INSP) is a medical technology company that develops and commercializes innovative, minimally invasive solutions for obstructive sleep apnea. The company offers Inspire therapy, which includes implantable components with a pressure-sensing lead, a stimulation lead, and a neurostimulator, operable through a remote control. While we acknowledge the potential of INSP as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey.
Business Insider
5 hours ago
- Business Insider
Google to commit $1B to support AI education, job training, research
In a blog post, Google wrote, 'Millions of college students around the world are getting ready to start classes. To help make the school year even better, we're making our most advanced AI tools available to them for free, including our new Guided Learning mode. We're also providing $1 billion to support AI education and job training programs and research in the U.S. This includes making our AI and career training free for every college student in America through our AI for Education Accelerator – over 100 colleges and universities have already signed up.' Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
